Previous 10 | Next 10 |
2023-07-27 11:13:07 ET InMode Ltd. (INMD) Q2 2023 Earnings Conference Call July 27, 2023, 08:30 AM ET Company Participants Miri Segal - Investor Relations, MS-IR LLC Moshe Mizrahy - Chairman and CEO Shakil Lakhani - President, North America Yair Malca - Chief...
2023-07-27 07:04:48 ET InMode press release ( NASDAQ: INMD ): Q2 Non-GAAP EPS of $0.72 beats by $0.06 . Revenue of $136.08M (+19.8% Y/Y) beats by $3.53M . FY2023 Outlook : Revenue between $530 million and $540 million; Non-GAAP gross margin between 83%...
InMode Reports Second Quarter 2023 Financial Results; Record Quarterly Revenue of $136.1M Represents 20% Year-Over-Year Growth PR Newswire YOKNEAM, Israel , July 27, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") , a leading global provider of inn...
2023-07-26 12:32:19 ET InMode ( NASDAQ: INMD ) is scheduled to announce Q2 earnings results on Thursday, July 27th, before market open. The consensus EPS Estimate is $0.66 (+11.9% Y/Y) and the consensus Revenue Estimate is $132.55M (+16.7% Y/Y). Over the last 2 years, ...
InMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve Patents PR Newswire YOKNEAM, Israel , July 25, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) (" InMode "), a leading global provider of innovative medical technol...
2023-07-18 10:59:50 ET Summary I discuss the investment potential of InMode, a company specializing in laser equipment for aesthetic medicine treatments, which has seen significant growth and offers high growth prospects with attractive profit margins. My analysis of InMode's busi...
2023-07-12 16:40:00 ET Shares of cosmetic medical device company InMode (NASDAQ: INMD) flew to new 52-week highs on Wednesday after the company released preliminary financial results for the second quarter of 2023 and raised its guidance for the year. As of 3:15 p.m. ET, InMode stoc...
2023-07-12 07:08:35 ET InMode ( NASDAQ: INMD ) reports Q2 revenue of $135.7 million to $135.9M vs. $130.26M consensus, Non-GAAP EPS of $0.70 to $0.71 vs. $0.64 consensus. Q2 Non-GAAP gross margin will be in the range of 83% to 85%. The company has ...
InMode Expects Second Quarter 2023 Revenue Between $135.7-$135.9M, Increases Full Year 2023 Guidance, Expects Revenues of $530-540M PR Newswire Conference call to be held on Thursday, July 27, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel , July 12, 2...
2023-07-11 09:00:00 ET Summary InMode's valuations have been discounted drastically compared to its 3Y means and its peers, suggesting its overly depressed price target of $48.30. However, we believe an upward revision to P/E of 18x is warranted, suggesting a more optimistic long-...
News, Short Squeeze, Breakout and More Instantly...
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling PR Newswire IRVINE, Calif. , July 17, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technolog...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...